Forensic Analysis · Pharmaceuticals & Biotechnology · as of Nov 9, 2026

Gilead Sciences, Inc. (GILD)

A forensic read on Gilead Sciences, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

A · High-quality, modest growth

Forensic grade

Safe

Financial health

3.3

Distress distance

Clean

Earnings quality

Forensic signals

40.5%

ROE

2.4%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Gilead Sciences, Inc. earns an A (High-quality, modest growth) forensic quality grade, and its balance-sheet distress test reads 3.3, placing it in the Safe zone. 1 forensic signal was flagged in its latest SEC filings, led by accruals ratio (% of NOA).

What the filings flag

+10.6%

FY2024→FY2025

Accruals ratio (% of NOA). Net operating assets grew +10.6% relative to their own average in FY2025 — scaled by NOA itself, not by total assets, which is what the Forensic Screens card's own accrual row divides by. Accruals are building faster than is comfortable — part of profit is sitting in the balance sheet rather than turning to cash. The build is led by payables paid down 14% against 0% in cost of sales and receivables up +11% against revenue +2%. A cash-flow measure on the same base disagrees: reported earnings ran in line with operating cash by 4% of net operating assets, against an accruals ratio of 10.6%. The two are computed differently: the accruals ratio is the change in net operating assets over average net operating assets, while the cash-flow figure is net income less operating cash flow over that same average. Read them as two results, not one.Accruals ratio: the year-over-year change in net operating assets, relative to their own average.NOA (net operating assets): the money tied up in running the business, operating assets minus operating liabilities.

Key fundamentals

Latest Revenue$29.44B

Revenue Growth YoY+2.4%

Revenue CAGR (2yr)+4.2%

Net Margin28.9%

Free Cash Flow$9.46B

Return on Equity40.5%

Debt / Equity1.10x

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Gilead Sciences, Inc.'s actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Nov 9, 2026. Forensic signals flag probability, not certainty.

See a wrong number? Report an error with the filing it should match.